Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
- PMID: 36775835
- PMCID: PMC10121291
- DOI: 10.3350/cmh.2023.0045
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Keywords: Fatty liver; Liver fibrosis; Non alcoholic steato-hepatitis; Non invasive markers.
Conflict of interest statement
The authors have no conflicts to disclose.
Comment on
-
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future.Clin Mol Hepatol. 2023 Feb;29(Suppl):S157-S170. doi: 10.3350/cmh.2022.0348. Epub 2022 Nov 22. Clin Mol Hepatol. 2023. PMID: 36417894 Free PMC article. Review.
References
-
- Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273. - PubMed
-
- Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–373. Erratum in: Lancet Gastroenterol Hepatol 2020;5:e3. - PMC - PubMed
-
- Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:970–985. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical